SANFER FARMA S.A.P.I. DE C.V. – Trademark Portfolio

Entity Type: 99

SANFER FARMA S.A.P.I. DE C.V. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 19 filings in this category. Currently, 9 trademarks are registered and 4 are pending. Notable registered marks include TABALON, ANDANTOL, AEROCLEAN, MICRODACYN, and SYNCOL MAX. The owner is based in CIUDAD DE MÉXICO.

BLVD. ADOLFO LÓPEZ MATEOS 314, INT. 3-A

COL. TLACOPAC

CIUDAD DE MÉXICO 01049 , MX

19 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

SANFER FARMA S.A.P.I. DE C.V.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (19 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SANFER FARMA S.A.P.I. DE C.V. have?

SANFER FARMA S.A.P.I. DE C.V. has 19 U.S. trademarks filed with the USPTO. Of these, 9 registered, 4 pending, 4 abandoned, 2 cancelled.

What trademark classes does SANFER FARMA S.A.P.I. DE C.V. file in?

SANFER FARMA S.A.P.I. DE C.V. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SANFER FARMA S.A.P.I. DE C.V.'s most well-known trademarks?

SANFER FARMA S.A.P.I. DE C.V.'s registered trademark portfolio includes well-known marks such as TABALON, ANDANTOL, AEROCLEAN, MICRODACYN, and SYNCOL MAX. These are among 9 currently registered trademarks in the portfolio.

What is SANFER FARMA S.A.P.I. DE C.V.'s trademark registration success rate?

SANFER FARMA S.A.P.I. DE C.V. has a 60% trademark registration rate, with 9 out of 15 resolved applications resulting in successful registration. Currently, 4 applications are pending review.